Witfire Elite provides pharmaceutical due diligence services built on the method used in every brief published here: every figure traced to a primary source, the strongest counter-argument stated in full, and the conclusion written so it can be proved wrong.
That work can be commissioned privately — on a target you are evaluating, a facility you depend on, a filing you are preparing, or a decision your board has already asked about twice.
How these pharmaceutical due diligence services differ from a consultant deck
Most advisory output is designed to be defensible. This is designed to be useful, which is a different thing, and it means accepting the risk of being specific.
- Every number traces to a filing, a dataset or a publication. Where a figure is widely circulated but cannot be traced, that is stated rather than repeated.
- The counter-case is written at full strength. If the strongest argument against the conclusion is not in the document, the document is incomplete.
- Conclusions carry dates. “Monitor closely” is not a finding. A judgment that can be checked against a fixed date is.
- Unverified is marked, never guessed. Gaps appear as gaps. A confident sentence built on an assumption is worse than an acknowledged hole.
- Recommendations name an actor and a deadline. Anything else is commentary.
No pitch deck, no case-study PDF. Read the method applied in public, then decide.
- Unicycive OLC CRL: The CMC Failure Behind a Biotech SelloffThird-party manufacturing risk, traced to the company’s own 8-K against contrary trade reporting
- Novo Nordisk Eli Lilly Lawsuit: What the Case Turns OnLitigation risk, evidence standards, and what it means for fifty-plus Indian semaglutide brands
- Sun Pharma Organon Deal: Why 2027 Decides EverythingAn $11.75bn acquisition read against the replacement gap underneath it
What can be commissioned
Facility & supplier risk check
CMC & manufacturing risk assessment
Regulatory & CRL readiness review
Due diligence on a target or partner
Investor brief or market analysis
Commissioned editorial
Four steps, no procurement theatre
Who this works for, and who it does not
What pharmaceutical due diligence services cost
Fees are quoted per engagement after the scope call, because a single-facility question and a multi-market diligence brief are not the same work. These are the bands most engagements fall into.
Most engagements start with a check. One facility, one supplier, one disputed claim — answered properly and bounded to that. It is not a smaller version of an assessment; it is a different question, and it is usually the one that needs answering first.
Scope narrows price more than anything else. A single site with a known inspection history is not the same work as a multi-market diligence brief, and the proposal reflects that. Where a question turns out to be narrower than expected, the fee comes down before work starts, not after.
Indian institutions are quoted in rupees throughout, at the rates shown. The scope call is free and carries no obligation — if the record cannot answer your question, that will be said on the call rather than after an invoice.
The team behind the briefs
Literature review, briefing assessment and research briefing are produced by a research team led by Dr. Akhilesh Vats and Anupriya Vats. Commissioned work is delivered by the same team, under the same method.
That team also runs a laboratory held to the standards these briefs assess. ACME Research Solutions is a GMP and ISO 9001:2015 certified pharmaceutical contract research organisation working in in vitro pharmacology and formulation development, and it has served more than 45 institutions across six countries.
The work behind the briefs
Cytotoxicity and viability testing under ISO 10993-5. IC50 determination by four-parameter logistic curve fitting. Franz diffusion cell permeation studies. Particle characterisation by dynamic light scattering and zeta potential. FTIR, HPLC and GLP study direction. Microemulsion and complex topical formulation development, from bench through stability.
This is why the manufacturing and evidence sections of these briefs read the way they do. A control strategy, a comparability requirement or a site-transfer package is not a term encountered in a filing and summarised. It is work that has to be documented, defended and passed on inspection — and a laboratory that fails at it does not get a second submission either.
The same applies to trial evidence. When a brief argues that two hazard ratios from separate trials cannot be subtracted, or that a preference survey of twenty patients is not market evidence, that judgment comes from running the assays and fitting the curves, not from reading about them.
Common questions
What are pharmaceutical due diligence services?
They assess a specific company, asset, facility or filing before a commercial decision is made. A diligence brief covers regulatory history, manufacturing dependencies, the quality of evidence behind headline data, and the questions a seller has not yet been asked. Unlike market research, it is applied to one decision rather than a category.
How much do these services cost?
A facility or supplier risk check is $800–1,200 (₹65,000–1,00,000). A focused assessment is $2,500–5,000 (₹2–4 lakh). A full diligence brief is $6,000–12,000 (₹5–10 lakh). Retained engagements start at $24,000 a year. Fees are confirmed in a written proposal after the scope call, which is free. Indian institutions are quoted in rupees.
What is a facility risk check?
A bounded review of one manufacturing site or supplier: inspection history, warning letters and Form 483 observations, current classification, and whether your exposure sits with the contractor you signed or a subcontractor below them. Four to six pages in three to five working days. In the Unicycive case, the deficient party was a subcontractor of the contract manufacturer — not the vendor the sponsor had contracted with.
What is a CMC risk assessment?
It examines where chemistry, manufacturing and controls could stop an approval: site inspection history, single-source exposure, subcontractor tiers you may not have contracted with directly, and the transfer pathway if a site has to change. In June 2026, three FDA rejections landed in nine days and none of them was clinical.
What is a CRL readiness review?
An assessment of an application before the regulator gives you one. It identifies the weakest layer — clinical, chemistry, or a facility you do not own — and sets out what a Complete Response Letter would most likely say.
How long does it take?
Three to five working days for a facility or supplier check. Two to three weeks for a focused assessment or readiness review. Three to four weeks for a full diligence brief. Turnaround is confirmed in writing before any work starts, and a narrower scope moves faster.
Do you work with Indian companies?
Yes, and pricing is quoted in rupees at local rates rather than converted from dollars. The team is based in India, and the underlying laboratory is a GMP and ISO 9001:2015 certified contract research organisation serving more than 45 institutions across six countries.
Describe the decision. Not the brief.
The most useful first message is one paragraph: what you are deciding, by when, and what is currently stopping you. Everything else can be worked out on the call.
Start a conversation → Email the editorIndependence. Commissioned work does not alter what is published on this site. Where a commissioned piece appears here, it is labelled as sponsored under the Advertising Policy, and the Editorial Policy and Corrections Policy apply to it exactly as they do to editorial.
Put this framework on your own file.
The same method used in these briefs, applied privately to a decision you are actually facing — a target, a partner, a facility, a filing.
- CMC & manufacturing risk assessment
- Regulatory / CRL readiness review
- Due diligence on a target or partner
- Investor brief or market analysis
- Commissioned editorial
- Something else